Clinical Trial Update: A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD) [Phase 4]

View source ↗

Summary

A Phase 4 multicenter crossover study evaluated the impact of QVA149 on nocturnal oxygen levels in COPD over 12 weeks total; study completed with posted results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• QVA149 (indacaterol/glycopyrronium)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Obstructive Pulmonary Disease | Phase 4 | Status: COMPLETED | Results posted: 2018-08-06